Nifty Labs is an API manufacturer based in India. It holds 8 valid CEPs across a filed portfolio of 8 molecules. Its GMP standing is certified by EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 25 September 2025 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Hyderabad, India | Not on file |
| NTR, India | Not on file |
| Ntr Dist, India | 3007025492 |
| Molecule | Regulators | Docs |
|---|---|---|
| Esomeprazole | EDQM, SFDA (Saudi Arabia) | 2 |
| Aripiprazole | EDQM | 1 |
| Doxazosin Mesilate | EDQM | 1 |
| Lansoprazole | EDQM | 1 |
| Quetiapine | EDQM | 1 |
| Quetiapine Fumarate | EDQM | 1 |
| Rabeprazole | EDQM | 1 |
| Rivaroxaban | EDQM | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 1 | None |
| EMA | None | 1 |
| US FDA | None | 1 |
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Nifty Labs comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.